Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Role of Academic Biobanks in Public-Private Partnerships in the European Biobanking and BioMolecular Resources Research Infrastructure Community.

Hämäläinen I, Törnwall O, Simell B, Zatloukal K, Perola M, van Ommen GB.

Biopreserv Biobank. 2019;17(1):46-51. doi: 10.1089/bio.2018.0024. Epub 2018 Nov 30.

PMID:
30499696
2.

Transnational access to large prospective cohorts in Europe: Current trends and unmet needs.

Simell BA, Törnwall OM, Hämäläinen I, Wichmann HE, Anton G, Brennan P, Bouvard L, Slimani N, Moskal A, Gunter M, Zatloukal K, Minion JT, Soini S, Mayrhofer MT, Murtagh MJ, van Ommen GJ, Johansson M, Perola M; BBMRI-LPC Consortium (FP7 GA no. 313010).

N Biotechnol. 2019 Mar 25;49:98-103. doi: 10.1016/j.nbt.2018.10.001. Epub 2018 Oct 17.

PMID:
30342241
3.

A toddler PCV booster dose following 3 infancy priming doses increases circulating serotype-specific IGG levels but does not increase protection against carriage.

Dagan R, Ben-Shimol S, Simell B, Greenberg D, Porat N, Käyhty H, Givon-Lavi N.

Vaccine. 2018 May 11;36(20):2774-2782. doi: 10.1016/j.vaccine.2018.04.007. Epub 2018 Apr 11.

PMID:
29655626
4.

The feasibility of salivary sample collection in an international pediatric cohort: The the TEDDY study.

Roth R, Baxter J, Vehik K, Hopkins D, Killian M, Gesualdo P, Melin J, Simell B, Strauss E, Lernmark Å, Johnson SB; TEDDY Study Group.

Dev Psychobiol. 2017 Jul;59(5):658-667. doi: 10.1002/dev.21523. Epub 2017 May 26.

5.

Colonisation endpoints in Streptococcus pneumoniae vaccine trials.

Auranen K, Rinta-Kokko H, Goldblatt D, Nohynek H, O'Brien KL, Satzke C, Simell B, Tanskanen A, Käyhty H; Pneumococcal Carriage Group (PneumoCarr).

Vaccine. 2013 Dec 17;32(1):153-8. doi: 10.1016/j.vaccine.2013.08.061. Epub 2013 Sep 7. Review.

PMID:
24016803
6.

Design questions for Streptococcus pneumoniae vaccine trials with a colonisation endpoint.

Auranen K, Rinta-Kokko H, Goldblatt D, Nohynek H, O'Brien KL, Satzke C, Simell B, Tanskanen A, Käyhty H.

Vaccine. 2013 Dec 17;32(1):159-64. doi: 10.1016/j.vaccine.2013.06.105. Epub 2013 Jul 18. Review.

7.

The fundamental link between pneumococcal carriage and disease.

Simell B, Auranen K, Käyhty H, Goldblatt D, Dagan R, O'Brien KL; Pneumococcal Carriage Group.

Expert Rev Vaccines. 2012 Jul;11(7):841-55. Review.

PMID:
22913260
8.

Serum IgM antibodies contribute to high levels of opsonophagocytic activities in toddlers immunized with a single dose of the 9-valent pneumococcal conjugate vaccine.

Simell B, Nurkka A, Ekström N, Givon-Lavi N, Käyhty H, Dagan R.

Clin Vaccine Immunol. 2012 Oct;19(10):1618-23. Epub 2012 Aug 8.

9.

Association of serotype-specific antibody concentrations and functional antibody titers with subsequent pneumococcal carriage in toddlers immunized with a 9-valent pneumococcal conjugate vaccine.

Simell B, Nurkka A, Lahdenkari M, Givon-Lavi N, Käyhty H, Dagan R, Jokinen J.

Clin Vaccine Immunol. 2012 Jan;19(1):96-9. doi: 10.1128/CVI.05369-11. Epub 2011 Nov 9.

10.

Aging reduces the functionality of anti-pneumococcal antibodies and the killing of Streptococcus pneumoniae by neutrophil phagocytosis.

Simell B, Vuorela A, Ekström N, Palmu A, Reunanen A, Meri S, Käyhty H, Väkeväinen M.

Vaccine. 2011 Feb 24;29(10):1929-34. doi: 10.1016/j.vaccine.2010.12.121. Epub 2011 Jan 12.

PMID:
21236231
11.

Pneumococcal carriage and acute otitis media induce serum antibodies to pneumococcal surface proteins CbpA and PhtD in children.

Simell B, Ahokas P, Lahdenkari M, Poolman J, Henckaerts I, Kilpi TM, Käyhty H.

Vaccine. 2009 Jul 23;27(34):4615-21. doi: 10.1016/j.vaccine.2009.05.071. Epub 2009 Jun 12.

PMID:
19524618
12.

Effects of ageing and gender on naturally acquired antibodies to pneumococcal capsular polysaccharides and virulence-associated proteins.

Simell B, Lahdenkari M, Reunanen A, Käyhty H, Väkeväinen M.

Clin Vaccine Immunol. 2008 Sep;15(9):1391-7. doi: 10.1128/CVI.00110-08. Epub 2008 Jul 2.

13.

Antibodies to pneumococcal surface protein A families 1 and 2 in serum and saliva of children and the risk of pneumococcal acute otitis media.

Simell B, Melin M, Lahdenkari M, Briles DE, Hollingshead SK, Kilpi TM, Kayhty H.

J Infect Dis. 2007 Nov 15;196(10):1528-36. Epub 2007 Oct 31. Erratum in: J Infect Dis. 2008 Mar 1;197(5):779-80.

PMID:
18008233
14.

Serum antibodies to the pneumococcal surface proteins PhtB and PhtE in Finnish infants and adults.

Holmlund E, Simell B, Jaakkola T, Lahdenkari M, Hamel J, Brodeur B, Kilpi T, Käyhty H.

Pediatr Infect Dis J. 2007 May;26(5):447-9.

PMID:
17468659
15.

Serum antibodies to pneumococcal neuraminidase NanA in relation to pneumococcal carriage and acute otitis media.

Simell B, Jaakkola T, Lahdenkari M, Briles D, Hollingshead S, Kilpi TM, Käyhty H.

Clin Vaccine Immunol. 2006 Oct;13(10):1177-9. Epub 2006 Aug 23.

17.

Pneumococcal carriage and otitis media induce salivary antibodies to pneumococcal capsular polysaccharides in children.

Simell B, Kilpi TM, Käyhty H.

J Infect Dis. 2002 Oct 15;186(8):1106-14. Epub 2002 Sep 16.

PMID:
12355361
18.

Pneumococcal carriage and otitis media induce salivary antibodies to pneumococcal surface adhesin a, pneumolysin, and pneumococcal surface protein a in children.

Simell B, Korkeila M, Pursiainen H, Kilpi TM, Käyhty H.

J Infect Dis. 2001 Mar 15;183(6):887-96. Epub 2001 Feb 21.

PMID:
11237805

Supplemental Content

Loading ...
Support Center